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While genome wide association studies as well as candidate gene studies have revealed a 
great deal of insight into the contribution of genetics to obesity development and 
susceptibility, advances in adipose tissue research have substantially changed the 
understanding of adipose tissue function. Its perception has changed from passive lipid 
storage tissue to active endocrine organ regulating and modulating whole body energy 
homeostasis and metabolism, inflammatory and immune responses by secreting a multitude of 
bioactive molecules, termed adipokines.  
The expression of human vaspin (serpinA12) is positively correlated to BMI and insulin 
sensitivity and increases glucose tolerance in vivo, suggesting a compensatory role in response 
to diminished insulin signaling in obesity. Recently, considerable insight has been gained into 
vaspin structure, function and specific target tissue dependent effects and several lines of 
evidence suggest vaspin as a promising candidate for drug development for the treatment of 
obesity related insulin resistance and inflammation. These will be summarized in this review 






In parallel to ongoing research efforts on how to provide sufficient food for the predicted ten-
plus billion people on this planet in the near future, the WHOs latest report on human obesity 
states 1.4 billion people as overweight, 30% of them obese [1]. There are now >60% more 
people overweight than undernourished (~850 million) and more deaths are linked to 
overweight than underweight [2]. To categorize obesity, the body mass index (BMI) is the 
most commonly used indicator of body mass and provides a basis to differentiate weight-
ranges [3]. Obesity is generally defined by a BMI of >30 kg/m² with overweight beginning at 
>25 kg/m². 
Overweight is caused by a chronic imbalance of energy intake and energy expenditure. 
Environmental, social and economical changes have massively changed dietary and physical 
activity patterns. Driven by globalized food markets, a transition to a westernized nutrition 
and an urbanized lifestyle, obesity is the fastest growing health problem worldwide [4]. While 
undernutrition issues remain unsolved in developing countries, access to cheap, energy-dense 
and nutrient-poor processed foods is in part changing the face of malnutrition putting 
especially the poor and the young in danger of going from undernourished to overweight [5]. 
Obesity seriously impairs the quality and length of life by raising morbidity and premature 
mortality [6-8]. With obesity, the rates of several common adverse medical conditions such as 
hypertension, type 2 diabetes, cardiovascular disease, stroke and cancer are significantly 
increased [9]. For most of these comorbidities the causal relationship to overweight and 
obesity has been established in weight loss studies demonstrating a diminished or eliminated 
degree of these conditions after body weight reduction [10, 11]. 
With over 50% of the European population being overweight or obese, direct costs of obesity 
have put a serious burden on healthcare systems and are accounting for an estimated 7% of 
total healthcare costs (~60 billion €) in the EU [12, 13]. Additionally, the indirect illness 
related economic costs due to loss of productivity are estimated to significantly exceed 100 
billion € per year in the EU [13]. Furthermore, with childhood obesity becoming more and 
more prevalent, the peak of the obesity epidemic is obviously yet to come. Consequently, 
identifying the various factors and understanding their function in the regulation of both 
energy intake and expenditure is an utmost important step towards developing obesity 
treatments, whether they will be based on environmental/lifestyle or pharmaceutical 
intervention.  
Social and economical changes have created an obesogenic environment around the globe. 
But the susceptibility to obesity among individuals living in the same obesogenic environment 
is very diverse, indicating genetic factors that are predisposing to obesity. Commonly, obesity 
is classified into two main subgroups, monogenic and polygenetic obesity where the latter 
represents the most common form of obesity. And while genome wide association studies as 
well as candidate gene studies have revealed a great deal of insight into the contribution of 
genetics to obesity development and susceptibility, advances in adipose tissue research have 
substantially changed the understanding of adipose tissue function. The perception of adipose 
tissue has changed from passive lipid storage tissue to active endocrine organ regulating and 
modulating whole body energy homeostasis and metabolism, inflammatory and immune 
responses. This crosstalk with all major organs is mainly achieved by secreting a multitude of 
bioactive molecules, termed adipokines (reviewed in [14]). As a consequence, condition, 
quantity and location of adipose tissue is reflected by the profile of adipokines it secretes and 
alterations in these secretion-patterns lead to disregulated metabolic (reviewed in [15, 16]), 
energetic (reviewed in [17]), immunologic (reviewed in [18, 19]), cardiovascular (reviewed in 
[20]) and cancerogenic (reviewed in [21]) processes and finally induce the various 
comorbidities of obesity. While healthy, adipose tissue secretion of adipokines is coordinated 
in an anti-inflammatory, insulin-sensitizing and cardioprotective pattern, but with increasing 
fat mass this secretion pattern flip-flops into a pro-inflammatory, insulin-resistant, atherogenic 
and along these lines fatal systemic environment. 
Thus, adipokines comprise great potential as novel targets for pharmacological treatment of 
obesity and related metabolic diseases. Very few adipokines such as adiponectin and leptin, 
have been extensively studied so that a substantial body of knowledge with respect to function 
and mode of action is established (reviewed in [22, 23]). Therefore, the identification of novel 
adipokines and the molecular characterization of their structure, function, mode of action and 
molecular targets remain the major challenges in basic obesity research. Several lines of 
evidence suggest visceral adipose tissue derived serpin (vaspin) as a promising candidate for 
drug development and will be summarized with a focus on molecular mechanisms and 
pathways in this review.  
 
Vaspin, a novel adipose tissue derived serpin family member 
Serpins (serine protease inhibitors) represent the largest, most broadly distributed and most 
functionally diverse superfamily of peptidase inhibitors. Both intracellular and extracellular 
serpins exist, exhibiting important regulatory roles in sensitive and fine-tuned processes such 
as blood coagulation, inflammation and host defense, fibrinolysis and ischemia protection [24, 
25]. Many serpins function as active serine protease inhibitors, but there are also non-
inhibitory serpins exerting effects as receptor ligands or chaperones. Over 1500 identified 
genes belong to the serpin family, and in humans 36 confirmed serpins have been categorized 
into nine clades (A to I) [24, 25]. Already eight members of the serpin family derived from six 
clades have been identified in the adipocyte secretome or proteome with the majority of them 
acting as extracellular protease inhibitors such as α1-anti-trypsin (serpinA1), anti-
chymotrypsin (serpinA3), plasminogen activator inhibitor (PAI1, serpinE1) or complement 1 
inhibitor (serpinG1) [26-28]. With HSP47 (serpinJ6), a chaperone protein assisting in protein 
folding, also a non-inhibitory serpin has been identified [28].  
Despite only moderate sequence homology, serpins exhibit well conserved structural core 
elements comprising a helical N-terminal domain, a C-terminal β-sheet domain, the 
functionally fundamental exposed reactive center loop (RCL) serving as the substrate for 
target proteases and the central five-stranded β-sheet (sheet A; Figure 1, left). Remarkably, 
the native serpin conformation (exposed RCL) is not the most stable and serpins are able to 
insert the RCL into the central β-sheet A and adopt a hyperstable conformation. The serpin 
inhibition mechanism is based on the stabilization of the protease-serpin complex as an acyl-
enzyme intermediate. After protease attack and proteolytic cleavage within the RCL 
(Figure 1, middle), the RCL is rapidly inserted into β-sheet A resulting in the hyperstable 
serpin conformation and significant deformation of the protease (Figure 1, right). The 
distortion of the catalytic center prevents final deacylation due to the inability of the protease 
to stabilize the required tetrahedral transition state.  
We have recently solved the crystal structure of human vaspin (PDB ID: 4IF8; 
http://www.rcsb.org/pdb/) [29]. As expected, vaspin features all typical structural core 
domains of native serpins with three β-sheets, nine α-helices and an exposed flexible RCL 
(extending from glycine 364 to proline 381 and not resolved in the crystal structure, Figure 
2a). Conserved small side-chain amino acids within the hinge region together with a non-
charged amino acid at position P14 within the RCL suggest vaspin to represent an inhibitory 
serpin targeting serine proteases presumably attacking between methionine 378 (P1) and 
glutamate 379 (P1´) in the RCL sequence (Figure 2b) [29]. With respect to potential protease 
targets, the P1´ glutamate is of special interest, as this represents a highly unusual residue at 
this position and very likely determines protease specificity.  
 
Vaspin, a beneficial serpin in obesity and diabetes 
Vaspin (serpinA12) was first identified as a putative member of the serpin family specifically 
expressed in the visceral adipose tissue of the rat type-2 diabetes model Otsuka Long-Evans 
Tokushima Fatty rat [30]. In this animal model expression levels of vaspin reached a 
maximum at the age when obesity and insulin plasma concentrations peaked and subsequently 
decreased with worsening of diabetes and concomitant body weight loss [31]. A study in 
Wistar rats confirmed significant expression of vaspin mRNA and protein in visceral and less 
pronounced in subcutaneous adipose tissue only after high fat diet induced obesity and 
development of insulin resistance [32]. In human adipose tissue, vaspin mRNA expression 
was found to be associated with obesity, insulin resistance and type 2 diabetes [33] and 
elevated vaspin serum concentrations are associated with obesity and impaired insulin 
sensitivity in humans [34, 35]. Already in childhood higher vaspin serum levels are associated 
with insulin resistance [36]. 
In addition to expression in white adipose tissue, we and others have demonstrated vaspin 
expression on the mRNA or protein level in several other tissues such as liver [36], stomach 
[37], pancreas [29, 36], skin [36, 38, 39] and hypothalamus [37]. In various studies, mean 
serum vaspin concentrations have been reported as ~1 ng/ml, ranging from 0.01 to 6.74 ng/ml 
[34, 35, 40, 41]. 
A number of interesting single nucleotide polymorphisms (SNP) within and around the vaspin 
gene have been identified influencing vaspin serum concentrations. We have identified 
several SNPs that map between the vaspin and kallistatin (serpinA4) gene and are 
significantly associated with vaspin serum concentrations. Of these, rs11160190 reached the 
lowest P-value in a meta-analysis (P=3.8x10-41) [42]. A minor allele of SNP rs77060950 
genetically defines a distinct group in the Japanese population that exhibits significantly 
higher serum levels (>10 ng/ml) by regulating vaspin transcriptional activity [34]. While both 
of these SNPs do not alter the vaspin coding sequence and thus protein structure, activity or 
half-life, the rare vaspin functional variant rs61757459 results in a truncated protein due to an 
early stop codon and thus affects circulating vaspin levels [43]. The change from arginine to a 
premature stop codon (vaspin.R211X) revealed expression of a truncated protein in both pro- 
and eukaryotic cell lines. Bacterial expression resulted in non-refoldable inclusion body 
formation and after expression in human embryonal kidney cells the truncated vaspin could 
only be detected in cell lysates, but not in supernatants. Since the N-terminal signal peptide 
and regulating secretory elements are still present, the vaspin fragment seems to be unable to 
adopt an autonomous protein folding and subsequently undergoes lysosomal degradation [43].  
The most intriguing finding in the initial publication on vaspin was that administration of 
vaspin to obese mice improved glucose tolerance and altered gene expression of candidate 
genes for insulin resistance, such as leptin, resistin, and Tnf-α, glucose transporter-4 and 
adiponectin [31]. Furthermore, administration of insulin significantly up-regulated vaspin 
mRNA in subcutaneous adipose tissue and to a lesser extent reduced expression in visceral 
adipose tissue. The authors suggested that vaspin expression may represent a compensatory 
mechanism to antagonize the action of unknown proteases up-regulated in obesity and with 
increasing insulin resistance, which blunt insulin action. However, proteases investigated in 
this study (trypsin, elastase, urokinase, factor Xa, collagenase, and dipeptidyl peptidase) were 
not inhibited by vaspin [31]. 
 
Vaspin inhibits kallikrein 7 
Based on the crystal structure data demonstrating that our expression system resulted in a 
most likely active protein and suggesting vaspin to be an inhibitory serpin, we aimed to 
identify target proteases and thereby unravel the presumed mechanistic basis of the intriguing 
beneficial metabolic effects of this serpin. Identification of a first target protease would 
further enable evaluation of the biological inhibitory activity in an assay based manner and 
thus the development of vaspin variants with modulated activity, specificity profiles or screen 
for activity modulating cofactors and molecules.  
We started investigating potential target proteases of the kallikrein (KLK) family, as KLK5 
has been reported to co-localize with vaspin in skin and a study on KLK7 substrate specificity 
was characterized using bovine insulin B-chain [44, 45]. Initial protease activity screens of the 
closely related KLKs 4, 5 and 7 using increasing molar excess of vaspin revealed specific 
inhibition of KLK7 and we could demonstrate stable complex formation and locate the 
cleavage site between the predicted methionine 378 and glutamate 379 [29].  
With an assay system to assess the activity of vaspin we were able to generate first non 
inhibitory variants (vaspinT365R and vaspinA369P) as molecular tools to investigate protease 
inhibition dependence of observed vaspin effects in in vitro and in vivo experiments. As the 
inhibition mechanism of serpins is critically dependent on RCL length and flexibility [46], the 
introduction of a positively charged arginine (vaspinT365R) or a turn-inducing proline 
(vaspinA369P) in the hinge region of the RCL sufficiently slows loop insertion after 
proteolytic attack and prevents stable complex formation and inhibition (Figure 2b). These 
vaspin mutants serve as substrate molecules for KLK7 [29].  
 
Vaspin, KLK7 and insulin action 
After the identification of KLK7 as a target protease we furthermore investigated degradation 
of native human insulin by KLK7 and identified multiple cleavage sites within the A and 
B chain congruent with or close to the cleavage sites of the insulin degrading enzyme. We 
found vaspin and KLK7 co-expressed in murine islets indicating a potential relevance of the 
vaspin-KLK7 interaction beginning with insulin secretion. Indeed, vaspin treatment of 
isolated islets resulted in increased insulin levels in islet supernatants under normal and 
increased glucose concentrations without affecting insulin secretion, as C-peptide levels were 
not changed [29].  
We confirmed previously described improved glucose tolerance after acute vaspin 
administration in different mouse strains, C57BL/6NTac and diabetic db/db mice, and could 
demonstrate the dependence of this in vivo effect on the vaspin serpin activity using the 
mutant vaspinA369P. Application of the inactive mutant failed to improve glucose tolerance. 
Furthermore, after a glucose challenge we detected significantly increased insulin serum 
levels in mice after vaspin treatment, all together suggesting KLK7 inhibition by vaspin as 
one underlying physiological mechanism for its compensatory action on obesity-induced 
insulin resistance [29]. 
This mechanism of action would imply an acute and increased demand of vaspin protein 
before or parallel to postprandial increase in blood glucose levels and subsequent insulin 
release and, due to the suicide mechanism of serpin action, should result in reduced vaspin 
protein levels shortly after. Several studies support this general concept, as it has been shown 
that vaspin expression follows a circadian rhythm with expression highs preceding 
postprandial insulin concentration peaks [47] and acute insulin administration decreases 
vaspin serum concentrations in humans [48]. And while long-term insulin therapy seemed to 
slightly increase serum vaspin levels in diabetic OLEFT rats [31], patients on insulin 
treatment display lower serum vaspin levels [49]. Also, an acute glucose challenge 
significantly decreased vaspin serum levels in hyperinsulinemic, but not normoinsulinemic 
obese adolescents [36] and increases vaspin expression and secretion from omental fat pads in 
humans [50]. As aforementioned, insulin administration increased vaspin mRNA expression 
in white adipose tissue in mice [31]. These data support the hypothesis of compensation for 
depleted vaspin serum levels after acute vaspin demand and consumption due to the suicide 
mechanism of protease inhibition before or parallel to insulin action. Until now, there is no 
data on possible diurnal or meal related changes in KLK7 expression or serum levels. 
Importantly, the beneficial metabolic effects of vaspin might still be mediated by vaspin 
regulating additional or different proteolytic cascades that impact glucose uptake and insulin 
levels. Also, receptors for stable serpin-enzyme complexes are known, that mediate the 
clearing of these complexes from circulation and trigger signaling pathways increasing serpin 
expression into cells [51, 52]. A receptor for the vaspin-protease complexes, KLK7 or yet 
unidentified proteases, is currently not known. 
 
Vaspin in obesity related inflammatory skin diseases 
A recent study investigated expression of vaspin in human skin in the context of obesity 
associated psoriasis and demonstrated pronounced expression in the epidermal layers of non 
leasional skin [38]. In leasional skin, vaspin expression was significantly decreased and the 
authors hypothesized a potential role of vaspin in the regulation of proteolytic cascades in 
skin desquamation and inflammatory cytokine activation. KLK7 was identified as stratum 
corneum chymotryptic enzyme [53], and its function in skin has been shown to include the 
desquamation process [53, 54] and also activation of the pro-inflammatory cytokine 
interleukin-1β [55, 56]. Overexpression of Klk7 in a transgenic mouse model resulted in 
increased epidermal thickness, hyperkeratosis and dermal inflammation, skin changes similar 
to inflammatory skin diseases in humans [57-59] and in humans KLK7 expression and 
activity in psoriatic leasions is increased in comparison to healthy or non leasional psoriatic 
skin [60], suggesting a potential role of KLK7 in the initiation or progress of psoriasis. We 
have recently demonstrated that also the pro-inflammatory adipokine chemerin is 
proteolytically activated by KLK7 and that both proteins are co-expressed in human skin with 
increased co-localization in psoriatic leasions [39]. We could also confirm vaspin expression 
in the stratum corneum and furthermore found a distinct co-localization of vaspin and KLK7 
in healthy skin, which was considerably decreased in psoriatic leasions, which might indicate 
a potential role for the vaspin-KLK7 system in inflammatory and obesity-associated skin 
diseases such as psoriasis.  
 
Vaspin and regulation of food intake 
Interestingly, we found that central vaspin administration leads to reduced food intake and has 
sustained blood glucose-lowering effects in mice [37]. This has since been confirmed in rats, 
where acute injection of vaspin in the hypothalamus was shown to decrease orexigenic 
neuropeptide Y while increasing anorexigenic proopio-melanocortin expression [61]. Data in 
the patent literature indicate that the anorexic effect of vaspin in mice is also dependent on the 
serpin functionality, as a non-inhibitory vaspin mutant did not alter food intake compared to 
the native protein [62]. As the only known target protease KLK7 is also expressed at 
relatively high levels in the central nervous system and in cerebrospinal fluid [63, 64], 
prolonged insulin stability could also in part explain the reduced food intake after vaspin 
administration, whether given centrally or intraperitoneally.  
An initial study on vaspin and human eating behavior also demonstrated an association of 
vaspin serum concentrations and eating behavior factors assessed by the German version of 
the Three-Factor Eating Questionnaire [65]. Nonetheless, conclusions with regards to the 
underlying causality remain elusive and genetic variations of the vaspin gene influencing 
vaspin serum concentrations were not associated with human eating behavior [65].  
 
Anti-inflammatory effects of vaspin 
On the cellular level, published data are mainly focused to vaspin effects on vascular 
endothelial cells and smooth muscle cells and demonstrates anti-inflammatory action and anti-
atherogenic effects in the context of obesity associated inflammation and cardio-vascular 
disease. Multiple lines of evidence suggest that vaspin protects endothelial cells from 
inflammation and apoptosis (Figure 3). A first study investigating the anti-inflammatory 
potential of vaspin on human umbilical vein endothelial cells (HUVEC) found no beneficial 
effects on TNF-α-induced inflammation and activation of downstream inflammatory 
pathways such as NF-κB, JNK and p38-MAPK (p38) [66]. But subsequent work on vascular 
smooth muscle cells (VSMC) could demonstrate vaspin inhibition of Tnf-α-induced 
expression of adhesion molecules in VSMC and subsequently decreased lymphocyte adhesion 
by a reducing reactive oxygen species (ROS) generation and activation of NF-κB and protein 
kinase C [67]. Furthermore, vaspin attenuates high glucose-induced VSMC proliferation and 
chemokinesis also by blocking ROS production as well as inhibition of Mapk, Pi3k/Akt, 
insulin receptor signaling and Nf-κb signaling pathways [68]. In a similar manner, vaspin 
protects human aortic endothelial cells (HAEC) against free fatty acid (FFA)-induced 
apoptosis by blunting the phosphatidylinositol 3-kinase (PI3K)/AKT pathway [69]. 
Methylglyoxal is a harmful glucose metabolite due to the inherent formation of advanced 
glycation endproducts and represents an additional factor promoting diabetes induced 
vascular inflammation and apoptosis [70, 71]. In HUVEC, vaspin was shown to inhibit 
methylglyoxal induced NADPH oxidase (NOX) activation  and subsequent ROS production, 
thus inhibiting apoptosis inducing caspase-3 cleavage and activation [72]. In addition to the 
inflammatory response, migration of smooth muscle cells plays an important role in the 
progress of atherosclerosis and vaspin has been shown to inhibit platelet-derived growth 
factor (PDGF)-BB induced VSMCs migration through inhibition of p38/Hsp27 signals also 
due to decreased ROS production [73]. Furthermore, nitric oxide (NO) and NO synthase 
(NOS) represent key regulators of vascular structure and tone. In HAEC, vaspin has been 
found to increase both NOS activity and NO levels by diminishing the cellular concentration 
of the NOS inhibitor asymmetric dimethylarginine (ADMA) [74]. These effects were based 
on activation of the transcription factor STAT3 and subsequent upregulation of gene 
expression of the ADMA metabolizing enzyme dimethylarginine dimethylaminohydrolase 
(DDAH). 
Importantly, none of the mentioned studies above have provided a mechanism of how the 
extracellular vaspin signal is transduced into the cell. A recent study has reported, that anti-
apoptotic effects of vaspin in HAEC appear at least in part to be mediated as a ligand of a 
membrane localized complex of 78 kDa glucose-regulated protein (GRP78) and voltage-
dependent anion channel (VDAC) [75]. Also in H4-II-E-C3 rat hepatocytes, GRP38 seems to 
be involved in vaspin induced intracellular signaling, e.g. activation of Akt and Ampk [76]. 
In adipose tissue, vaspin was reported to exert anti-inflammatory effects due to inhibition of 
pro-inflammatory adipocytokine expression (e.g. resistin and Tnf-α) in murine white adipose 
tissue [31], and a recent study reported vice versa Tnf-α mediated reduction of vaspin 
expression in 3T3-L1 adipocytes during differentiation [77]. Nevertheless, distinct direct 
effects and underlying molecular pathways of vaspin action on adipocytes, e.g. adipogenesis, 
adipocyte differentiation and adipose tissue function remain unknown. 
 
Vaspin and first links to osteoporosis 
Two studies have provided first evidence of anti-osteoporosis potential of vaspin. A fine 
tuned equilibrium between bone resorption by osteoclasts and bone formation by osteoblasts 
is fundamental for skeleton strength and integrity with osteoporosis developing when bone 
resorption exceeds bone formation. Vaspin seems to protect osteoblasts from apoptosis by 
upregulating apoptosis inhibitor Bcl-2 and decreasing expression of apoptosis activator Bax 
via activation of the ERK pathway [78]. On the other hand, osteoclast formation was found to 
be diminished by vaspin via blocking of receptor activator of nuclear factor-κB ligand 
(RANKL) induced activation of nuclear factor of activated T cells c1, matrix 
metalloproteinase-9 and cathepsin K in two types of osteoclast precursors [79]. Again, 
whether these intriguing effects of the adipokine vaspin on bone metabolism are dependent on 
inhibition of a protease, KLK7 or yet unidentified targets, or rely on interaction with a 
membrane bound receptor, as a free ligand or in complex with its target protease, remains to 
be investigated. 
 
Gain and loss of vaspin function in animal models 
Recently, first data on adipose tissue-specific (under control of the adipocyte fatty acid 
binding protein aP2-promoter) vaspin gain and loss of function in animal models have been 
published. In line with the hypothesis of vaspin representing a compensatory molecule in 
metabolically challenged or inflamed conditions, vaspin transgenic and knock-out mice 
exhibit inconspicuous phenotype under normal, e.g. chow fed conditions [76]. While activity 
and food intake were unaltered, vaspin transgenic mice under a high-fat diet gained less body 
weight with reduced liver and adipose tissue weight. As observed for acute vaspin 
administration, transgenic vaspin overexpression resulted in improved glucose and insulin 
tolerance without influencing adiponectin expression levels, a known insulin sensitizing 
adipokine. In the adipose tissue, macrophage infiltration and crown-like-structure occurrence 
was reduced and adipocyte hypertrophy was ameliorated. In agreement with these findings, 
vaspin knock-out mice featured the adverse, opposite phenotype under high fat diet [76].  
Interestingly, the most pronounced effects under diet induced obesity were observed in the 
liver of vaspin transgenic mice. Liver lipid droplet number and size as well as total 
triglyceride content were significantly reduced in combination with a downregulation of 
gluconeogenic and lipogenic gene expression. Serum pro-inflammatory Il-6 levels were 
significantly downregulated and adipose tissue microarray analysis revealed an immune 
response gene expression pattern comparable to normal chow fed control mice [76]. Together, 
the findings in transgenic and knock-out mice corroborate the data from in vitro and in vivo 




In conclusion, the reviewed data demonstrates that vaspin is a truly intriguing serpin with 
promising beneficial effects in obesity and related insulin resistance and inflammatory 
diseases of the skin and cardio-vascular system. The identification of further proteases and 
substrates thereof, which are inhibited and regulated by vaspin together with a detailed and 
better understanding of vaspin action may be the basis for future pharmacologic treatment 
strategies. Along these lines, the regulation of vaspin activity by small molecules, 
glucosaminoglycans or other cofactors, as described for many other inhibitory serpins 
(reviewed in [80]), has not been investigated yet and might lead to new strategies for 
pharmaceutical intervention and modulation of activity. 
The unexpected finding of significant effects of adipose tissue specific vaspin overexpression 
on the liver of transgenic mice indicates that the understanding of vaspin target tissues and 
mechanisms of target tissue specific effects, whether as a ligand of membrane bound 
receptors or as a serine protease inhibitor, is far from complete. More research is needed to 
understand and ultimately utilize and translate this intriguing potential in obesity, diabetes or 
inflammation treatment.  
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Figure 1. Serpin structure and inhibition mechanism. The exposed reactive center loop of 
the native serpin (left) is attacked by the target protease forming the initial Michaelis complex 
(middle) (PDB ID: 1OPH, [81]). After proteolytic cleavage, rapid insertion of the RCL into β-
sheet A results in the stable acyl-enzyme complex and significant deformation of the protease 
catalytic center prevents deacylation (right) (PDB ID: 2D26, [82]). 
 
 
Figure 2. Crystal structure of human vaspin. (a) The highly flexible RCL (including the 
unresolved residues 365-377 in the X-ray structure) are illustrated in red (PDB ID: 4IF8, 
[29]). (b) Detailed view of important residues within the RCL and the hinge region. The 
scissile bond residues P1 (M378) and P1’ (G379) for KLK7 are presented in blue, mutations 
within the hinge region resulting in substrate vaspin variants for KLK7 (T365R and A369P) 
in green. 
 Figure 3. Anti-inflammatory and anti-apoptotic effects of vaspin. Molecular pathways that 
are affected by vaspin and underlie its beneficial effects in endothelial and vascular smooth 
muscle cells (pathways impaired are marked with a red symbol, induced effects with a green 
symbol). Vaspin inhibits TNF-α, PDGF, methylglyoxal and high glucose induced ROS 
formation and subsequently inhibits cell apoptosis (reduced caspase3 activity), monocyte 
adhesion (reduced ICAM1 expression), cytoskeletal reorganization and migration (reduced 
expression of activation of p38 and HSP27). Vaspin increases intracellular NO via STAT3 
induced expression of DDAH and also by increasing AKT signaling. FFA induced apoptosis 
is inhibited also by increased IRS1/AKT signaling and reduced caspase3 activity. IR: insulin 
receptor; TNFR: TNF receptor; PDGFR: PDGF receptor. 
